JAK 抑制剂治疗难治性皮肌炎：病例系列

IF 2.2 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2024-06-18 DOI:10.1111/ajd.14335

L. Corbella-Bagot MD, X. Bosch-Amate MD, E. Gimeno-Ribes MD, J. Gil-Lianes MD, P. Giavedoni MD, J. C. Milisenda MD, S. Prieto-González MD, R. Hurtado García, J. M. Mascaró Jr MD

{"title":"JAK 抑制剂治疗难治性皮肌炎：病例系列","authors":"L. Corbella-Bagot MD, X. Bosch-Amate MD, E. Gimeno-Ribes MD, J. Gil-Lianes MD, P. Giavedoni MD, J. C. Milisenda MD, S. Prieto-González MD, R. Hurtado García, J. M. Mascaró Jr MD","doi":"10.1111/ajd.14335","DOIUrl":null,"url":null,"abstract":"<p>This retrospective cohort study assessed the efficacy and safety of Janus kinase (JAK) inhibitors, tofacitinib and baricitinib, in 14 patients with refractory dermatomyositis (DM), a multisystemic autoimmune disorder with limited therapeutic options. Results demonstrated a significant median decrease of 21 points and a 76% reduction in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores, along with a complete resolution of muscular symptoms in 64% of the patients. JAK inhibitors were effective in managing refractory DM across various subtypes with mild and manageable adverse events.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"588-592"},"PeriodicalIF":2.2000,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14335","citationCount":"0","resultStr":"{\"title\":\"JAK inhibitors in refractory dermatomyositis: A case series\",\"authors\":\"L. Corbella-Bagot MD, X. Bosch-Amate MD, E. Gimeno-Ribes MD, J. Gil-Lianes MD, P. Giavedoni MD, J. C. Milisenda MD, S. Prieto-González MD, R. Hurtado García, J. M. Mascaró Jr MD\",\"doi\":\"10.1111/ajd.14335\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>This retrospective cohort study assessed the efficacy and safety of Janus kinase (JAK) inhibitors, tofacitinib and baricitinib, in 14 patients with refractory dermatomyositis (DM), a multisystemic autoimmune disorder with limited therapeutic options. Results demonstrated a significant median decrease of 21 points and a 76% reduction in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores, along with a complete resolution of muscular symptoms in 64% of the patients. JAK inhibitors were effective in managing refractory DM across various subtypes with mild and manageable adverse events.</p>\",\"PeriodicalId\":8638,\"journal\":{\"name\":\"Australasian Journal of Dermatology\",\"volume\":\"65 7\",\"pages\":\"588-592\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14335\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australasian Journal of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ajd.14335\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajd.14335","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

这项回顾性队列研究评估了 Janus 激酶 (JAK) 抑制剂托法替尼和巴利昔替尼对 14 名难治性皮肌炎 (DM) 患者的疗效和安全性。结果显示，皮肤皮肌炎疾病面积和严重程度指数（CDASI）评分的中位数大幅下降了21分，降幅达76%，64%的患者肌肉症状完全缓解。JAK抑制剂能有效治疗各种亚型的难治性皮肌炎，且不良反应轻微、可控。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

JAK inhibitors in refractory dermatomyositis: A case series

This retrospective cohort study assessed the efficacy and safety of Janus kinase (JAK) inhibitors, tofacitinib and baricitinib, in 14 patients with refractory dermatomyositis (DM), a multisystemic autoimmune disorder with limited therapeutic options. Results demonstrated a significant median decrease of 21 points and a 76% reduction in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores, along with a complete resolution of muscular symptoms in 64% of the patients. JAK inhibitors were effective in managing refractory DM across various subtypes with mild and manageable adverse events.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.